Literature DB >> 15607965

Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity.

Clodagh C O'Shea1, Leisa Johnson, Bridget Bagus, Serah Choi, Cory Nicholas, Annie Shen, Larry Boyle, Kusum Pandey, Conrado Soria, John Kunich, Yuqiao Shen, Gaston Habets, Dave Ginzinger, Frank McCormick.   

Abstract

ONYX-015 is an adenovirus that lacks the E1B-55K gene product for p53 degradation. Thus, ONYX-015 was conceived as an oncolytic virus that would selectively replicate in p53-defective tumor cells. Here we show that loss of E1B-55K leads to the induction, but not the activation, of p53 in ONYX-015-infected primary cells. We use a novel adenovirus mutant, ONYX-053, to demonstrate that loss of E1B-55K-mediated late viral RNA export, rather than p53 degradation, restricts ONYX-015 replication in primary cells. In contrast, we show that tumor cells that support ONYX-015 replication provide the RNA export function of E1B-55K. These data reveal that tumor cells have altered mechanisms for RNA export and resolve the controversial role of p53 in governing ONYX-015 oncolytic selectivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15607965     DOI: 10.1016/j.ccr.2004.11.012

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  141 in total

1.  Timely synthesis of the adenovirus type 5 E1B 55-kilodalton protein is required for efficient genome replication in normal human cells.

Authors:  Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

2.  Morphological, Biochemical, and Functional Study of Viral Replication Compartments Isolated from Adenovirus-Infected Cells.

Authors:  Paloma Hidalgo; Lourdes Anzures; Armando Hernández-Mendoza; Adán Guerrero; Christopher D Wood; Margarita Valdés; Thomas Dobner; Ramón A Gonzalez
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

3.  Viral and Cellular Genomes Activate Distinct DNA Damage Responses.

Authors:  Govind A Shah; Clodagh C O'Shea
Journal:  Cell       Date:  2015-08-27       Impact factor: 41.582

Review 4.  Oncolytic Virotherapy for the Treatment of Malignant Glioma.

Authors:  Paul M Foreman; Gregory K Friedman; Kevin A Cassady; James M Markert
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

5.  Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts.

Authors:  Ramon Gonzalez; Wenying Huang; Renee Finnen; Courtney Bragg; S J Flint
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review).

Authors:  Lena J Gamble; Anton V Borovjagin; Qiana L Matthews
Journal:  Exp Ther Med       Date:  2010-03       Impact factor: 2.447

Review 7.  Reovirus: a targeted therapeutic--progress and potential.

Authors:  Radhashree Maitra; Mohammad H Ghalib; Sanjay Goel
Journal:  Mol Cancer Res       Date:  2012-10-04       Impact factor: 5.852

8.  Reduced infectivity of adenovirus type 5 particles and degradation of entering viral genomes associated with incomplete processing of the preterminal protein.

Authors:  Sayuri E Kato; Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

Review 9.  Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Authors:  Maria G Castro; Marianela Candolfi; Thomas J Wilson; Alexandra Calinescu; Christopher Paran; Neha Kamran; Carl Koschmann; Mariela A Moreno-Ayala; Hikmat Assi; Pedro R Lowenstein
Journal:  Expert Opin Biol Ther       Date:  2014-04-29       Impact factor: 4.388

Review 10.  Long story short: p53 mediates innate immunity.

Authors:  Jessica Miciak; Fred Bunz
Journal:  Biochim Biophys Acta       Date:  2016-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.